AT
Therapeutic Areas
Aurion Biotech Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Vyznova | Bullous Keratopathy (Corneal Endothelial Disease) | Approved/Commercial |
| AURN001 (neltependocel + Y-27632) | Corneal Endothelial Disease | Phase 3 |
| Cryopreserved AURN001 | Corneal Endothelial Disease | Clinical Stage |
Leadership Team at Aurion Biotech
AL
Arnaud Lacoste, PhD, MBA
Co-founder, Chief Executive Officer and Chief Scientific Officer
EP
Eris P. Jordan, OD
Co-founder and Chief Development Officer
EJ
Edward J. Holland, MD
Chief Medical Officer
SC
Sterling Chung
Chief Regulatory & Quality Officer
BS
Brad Shutzberg
Vice President, Finance & Infrastructure
SR
Sara Rosetti, PhD
Vice President, Human Resources
JO
J.D. Osborne, MBA
Vice President, Alliance Management
JW
Jen Watts, M.S.
Vice President, Global Head of Clinical Operations
HC
Heidi Chandler
Executive Director, Head of Program Management
MF
Marjan Farid, MD
Chair of Medical Advisory Board